Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: An observational study

BMC Gastroenterology

Volumn 12, Issue , 2012, Pages

  Manz, Michael ^a   Burri, Emanuel ^a,b   Rothen, Claude ^c   Tchanguizi, Nuschin ^a   Niederberger, Christian ^d   Rossi, Livio ^a   Beglinger, Christoph ^a   Lehmann, Frank S ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c Rothen Medical Laboratories   (Switzerland)

^d BÜHLMANN Laboratories AG   (Switzerland)

Author keywords

Biomarker; Diagnosis; Endoscopy; Gastroenterology

Indexed keywords

CALGRANULIN; BIOLOGICAL MARKER;

ABDOMINAL DISCOMFORT; ADENOMATOUS POLYP; ADULT; AGED; ARTICLE; COLONOSCOPY; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIVERTICULITIS; DUODENITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EROSIVE GASTRITIS; ESOPHAGITIS; FECES LEVEL; FEMALE; GASTROINTESTINAL ENDOSCOPY; HUMAN; ISCHEMIC COLITIS; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; PROTEIN ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STOMACH CARCINOMA; STOMACH ULCER; SWITZERLAND; ULCERATIVE COLITIS; ABDOMINAL PAIN; CHEMISTRY; EVALUATION; FECES; GASTROINTESTINAL DISEASE; HOSPITALIZATION; METABOLISM; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; RISK FACTOR; STOMACH MUCOSA;

ABDOMINAL PAIN; ADULT; AGED; BIOLOGICAL MARKERS; ENDOSCOPY, GASTROINTESTINAL; FECES; FEMALE; GASTRIC MUCOSA; GASTROINTESTINAL DISEASES; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 84855506791     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-12-5     Document Type: Article

References (48)

1. Kay L, Jorgensen T. Abdominal symptom associations in a longitudinal study. Int J Epidemiol 1993, 22(6):1093-1100. 10.1093/ije/22.6.1093, 8144291.
2. Kay L, Jorgensen T, Schultz-Larsen K. Abdominal pain in a 70-year-old Danish population. An epidemiological study of the prevalence and importance of abdominal pain. J Clin Epidemiol 1992, 45(12):1377-1382. 10.1016/0895-4356(92)90199-W, 1460475.
3. Group TDDS. Value of the unaided clinical diagnosis in dyspeptic patients in primary care. Am J Gastroenterol 2001, 96(5):1417-1421.
4. Jellema P, van der Windt DAWM, Schellevis FG, van der Horst HE. Systematic review: accuracy of symptom-based criteria for diagnosis of irritable bowel syndrome in primary care. Alimentary Pharmacology & Therapeutics 2009, 30(7):695-706. 10.1111/j.1365-2036.2009.04087.x, 22150533.
5. Hillila MT, Farkkila MA. Prevalence of irritable bowel syndrome according to different diagnostic criteria in a non-selected adult population. Aliment Pharmacol Ther 2004, 20(3):339-345. 10.1111/j.1365-2036.2004.02034.x, 15274671.
6. Tack J, Talley NJ, Camilleri M, Holtmann G, Hu P, Malagelada J-R, Stanghellini V. Functional gastroduodenal disorders. Gastroenterology 2006, 130(5):1466-1479. 10.1053/j.gastro.2005.11.059, 16678560.
7. Dalrymple J, Bullock I. Diagnosis and management of irritable bowel syndrome in adults in primary care: summary of NICE guidance. BMJ 2008, 336(7643):556-558. 10.1136/bmj.39484.712616.AD, 2265348, 18325967.
8. Drossman DA, Corazziari E, Delvaux M, Spiller R, Talley NJ, Thompson WG. [Appendix B: Rome III diagnostic criteria for functional gastrointestinal disorders.]. Rev Gastroenterol Mex 2010, 75(4):511-516.
9. Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol 1999, 34(1):50-54. 10.1080/00365529950172835, 10048733.
10. Gisbert JP, McNicholl AG. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig Liver Dis 2009, 41(1):56-66. 10.1016/j.dld.2008.05.008, 18602356.
11. van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010, 341:c3369. 10.1136/bmj.c3369, 2904879, 20634346.
12. Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 2002, 123(2):450-460. 10.1053/gast.2002.34755, 12145798.
13. D'Inca R, Dal Pont E, Di Leo V, Ferronato A, Fries W, Vettorato MG, Martines D, Sturniolo GC. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis 2007, 22(4):429-437. 10.1007/s00384-006-0159-9, 16838143.
14. D'Inca R, Dal Pont E, Di Leo V, Benazzato L, Martinato M, Lamboglia F, Oliva L, Sturniolo GC. Can calprotectin predict relapse risk in inflammatory bowel disease?. Am J Gastroenterol 2008, 103(8):2007-2014. 10.1111/j.1572-0241.2008.01870.x, 18802997.
15. Tibble J, Sigthorsson G, Foster R, Sherwood R, Fagerhol M, Bjarnason I. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut 2001, 49(3):402-408. 10.1136/gut.49.3.402, 1728420, 11511563.
16. Wildt S, Nordgaard-Lassen I, Bendtsen F, Rumessen JJ. Metabolic and inflammatory faecal markers in collagenous colitis. Eur J Gastroenterol Hepatol 2007, 19(7):567-574. 10.1097/MEG.0b013e328058ed76, 17556903.
17. Shastri YM, Bergis D, Povse N, Schäfer V, Shastri S, Weindel M, Ackermann H, Stein J. Prospective multicenter study evaluating fecal calprotectin in adult acute bacterial diarrhea. Am J Med 2008, 121(12):1099-1106. 10.1016/j.amjmed.2008.06.034, 19028207.
18. Maiden L, Thjodleifsson B, Theodors A, Gonzalez J, Bjarnason I. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology 2005, 128(5):1172-1178. 10.1053/j.gastro.2005.03.020, 15887101.
19. Summerton CB, Longlands MG, Wiener K, Shreeve DR. Faecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol 2002, 14(8):841-845. 10.1097/00042737-200208000-00005, 12172403.
20. Roseth AG, Kristinsson J, Fagerhol MK, Schjonsby H, Aadland E, Nygaard K, Roald B. Faecal calprotectin: a novel test for the diagnosis of colorectal cancer?. Scand J Gastroenterol 1993, 28(12):1073-1076. 10.3109/00365529309098312, 8303210.
21. Meucci G, D'Inca R, Maieron R, Orzes N, Vecchi M, Visentini D, Minoli G, Dal Pont E, Zilli M, Benedetti E, et al. Diagnostic value of faecal calprotectin in unselected outpatients referred for colonoscopy: A multicenter prospective study. Dig Liver Dis 2010, 42(3):191-195. 10.1016/j.dld.2009.07.002, 19695969.
22. Van Assche G, Dignass A, Panes J, Beaugerie L, Karagiannis J, Allez M, Ochsenkuhn T, Orchard T, Rogler G, Louis E, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. J Crohns Colitis 2010, 4(1):7-27.
23. Stange EF, Travis SP, Vermeire S, Reinisch W, Geboes K, Barakauskiene A, Feakins R, Flejou JF, Herfarth H, Hommes DW, et al. European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. J Crohns Colitis 2008, 2(1):1-23.
24. Allum WH, Griffin SM, Watson A, Colin-Jones D. Guidelines for the management of oesophageal and gastric cancer. Gut 2002, 50(Suppl 5):v1-23. 1867706, 12049068.
25. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008, 149(9):627-637.
26. Roseth AG, Fagerhol MK, Aadland E, Schjonsby H. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992, 27(9):793-798. 10.3109/00365529209011186, 1411288.
27. Carley S, Dosman S, Jones SR, Harrison M. Simple nomograms to calculate sample size in diagnostic studies. Emerg Med J 2005, 22(3):180-181. 10.1136/emj.2003.011148, 1726700, 15735264.
28. Sonnenberg A, Amorosi SL, Lacey MJ, Lieberman DA. Patterns of endoscopy in the United States: analysis of data from the Centers for Medicare and Medicaid Services and the National Endoscopic Database. Gastrointest Endosc 2008, 67(3):489-496. 10.1016/j.gie.2007.08.041, 18179793.
29. Heuss LT, Froehlich F, Beglinger C. Changing patterns of sedation and monitoring practice during endoscopy: results of a nationwide survey in Switzerland. Endoscopy 2005, 37(2):161-166. 10.1055/s-2004-826143, 15692932.
30. Vader JP, Wietlisbach V, Harris JK, Burnand B, Froehlich F, Gonvers JJ. Gastroenterologists overestimate the appropriateness of colonoscopies they perform: an international observational study. Endoscopy 2005, 37(9):840-846. 10.1055/s-2005-870193, 16116535.
31. Wallace MB, Durkalski VL, Vaughan J, Palesch YY, Libby ED, Jowell PS, Nickl NJ, Schutz SM, Leung JW, Cotton PB. Age and alarm symptoms do not predict endoscopic findings among patients with dyspepsia: a multicentre database study. Gut 2001, 49(1):29-34. 10.1136/gut.49.1.29, 1728370, 11413107.
32. Lasson A, Kilander A, Stotzer PO. Diagnostic yield of colonoscopy based on symptoms. Scand J Gastroenterol 2008, 43(3):356-362. 10.1080/00365520701679116, 18938663.
33. Ang YS, Macaleenan N, Mahmud N, Keeling PW, Kelleher DP, Weir DG. The yield of colonoscopy in average-risk patients with non-specific colonic symptoms. Eur J Gastroenterol Hepatol 2002, 14(10):1073-1077. 10.1097/00042737-200210000-00007, 12362097.
34. Lieberman DA, de Garmo PL, Fleischer DE, Eisen GM, Chan BK, Helfand M. Colonic neoplasia in patients with nonspecific GI symptoms. Gastrointest Endosc 2000, 51(6):647-651. 10.1067/mge.2000.105082, 10840294.
35. Vader JP, Burnand B, Froehlich F, Dubois RW, Bochud M, Gonvers JJ. The European Panel on Appropriateness of Gastrointestinal Endoscopy (EPAGE): project and methods. Endoscopy 1999, 31(8):572-578. 10.1055/s-1999-71, 10571128.
36. Juillerat P, Peytremann-Bridevaux I, Vader JP, Arditi C, Schussele Filliettaz S, Dubois RW, Gonvers JJ, Froehlich F, Burnand B, Pittet V. Appropriateness of colonoscopy in Europe (EPAGE II). Presentation of methodology, general results, and analysis of complications. Endoscopy 2009, 41(3):240-246. 10.1055/s-0028-1119643, 19280536.
37. Appropriate use of gastrointestinal endoscopy. American Society for Gastrointestinal Endoscopy. Gastrointest Endosc 2000, 52(6):831-837.
38. Chan YM, Goh KL. Appropriateness and diagnostic yield of EGD: a prospective study in a large Asian hospital. Gastrointest Endosc 2004, 59(4):517-524. 10.1016/S0016-5107(04)00002-1, 15044888.
39. Grassini M, Verna C, Niola P, Navino M, Battaglia E, Bassotti G. Appropriateness of colonoscopy: diagnostic yield and safety in guidelines. World J Gastroenterol 2007, 13(12):1816-1819. discussion 1819.
40. van der Sluijs Veer G, van den Hoven B, Russel MG, van den Bergh FA. Time-resolved fluorimetric immunoassay of calprotectin: technical and clinical aspects in diagnosis of inflammatory bowel diseases. Clin Chem Lab Med 2006, 44(3):292-298. 10.1515/CCLM.2006.051, 16519601.
41. Ikenberry SO, Harrison ME, Lichtenstein D, Dominitz JA, Anderson MA, Jagannath SB, Banerjee S, Cash BD, Fanelli RD, Gan S-I, et al. The role of endoscopy in dyspepsia. Gastrointest Endosc 2007, 66(6):1071-1075. 10.1016/j.gie.2007.07.007, 18028927.
42. Buri L, Hassan C, Bersani G, Anti M, Bianco MA, Cipolletta L, Di Giulio E, Di Matteo G, Familiari L, Ficano L, et al. Appropriateness Guidelines and Predictive Rules to Select Patients for Upper Endoscopy: A Nationwide Multicenter Study. Am J Gastroenterol 2009,
43. Miwa H, Yokoyama T, Hori K, Sakagami T, Oshima T, Tomita T, Fujiwara Y, Saita H, Itou T, Ogawa H, et al. Interobserver agreement in endoscopic evaluation of reflux esophagitis using a modified Los Angeles classification incorporating grades N and M: a validation study in a cohort of Japanese endoscopists. Dis Esophagus 2008, 21(4):355-363. 10.1111/j.1442-2050.2007.00788.x, 18477259.
44. Joshi S, Lewis SJ, Creanor S, Ayling RM. Age-related faecal calprotectin, lactoferrin and tumour M2-PK concentrations in healthy volunteers. Ann Clin Biochem 2010, 47(Pt 3):259-263.
45. Montalto M, Santoro L, Dalvai S, Curigliano V, D'onofrio F, Scarpellini E, Cammarota G, Panunzi S, Gallo A, Gasbarrini A, et al. Fecal calprotectin concentrations in patients with small intestinal bacterial overgrowth. Digestive diseases (Basel, Switzerland) 2008, 26(2):183-186.
46. Montalto M, Santoro L, Curigliano V, D'onofrio F, Cammarota G, Panunzi S, Ricci R, Gallo A, Grieco A, Gasbarrini A, et al. Faecal calprotectin concentrations in untreated coeliac patients. Scand J Gastroenterol 2007, 42(8):957-961. 10.1080/00365520601173632, 17613925.
47. Carroccio A, Iacono G, Cottone M, Di Prima L, Cartabellotta F, Cavataio F, Scalici C, Montalto G, Di Fede G, Rini G, et al. Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem 2003, 49(6 Pt 1):861-867.
48. Lorenz E, Muhlebach MS, Tessier PA, Alexis NE, Duncan Hite R, Seeds MC, Peden DB, Meredith W. Different expression ratio of S100A8/A9 and S100A12 in acute and chronic lung diseases. Respir Med 2008, 102(4):567-573. 10.1016/j.rmed.2007.11.011, 2347354, 18164192.